Immunovant Stock Forecast
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 1:47 PM ET
IMVT analyst consensus
Consensus (17 analysts)
buy
Avg. price target
$48.88+61.00%
- Strong buy 2
- Buy 11
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 17 Wall Street analysts covering Immunovant (2026-10-07), 13 rate the stock a buy or strong buy, 4 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $48.88, with a high estimate of $66.00 and a low estimate of $30.00. The average target implies upside of 61.0% from the current price of $30.36.
The spread between the highest and lowest targets is 120.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IMVT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 12% |
| Buy | 11 | 65% |
| Hold | 4 | 24% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $30.00 | -1.19% |
| Average target | $48.88 | +61.00% |
| High target | $66.00 | +117.39% |